



## **LASA SUPERGENERICS LIMITED**

**CORPORATE OFFICE:** B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India.  
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

**Ref. No.: LASA/SE/20-21/016**

**Wednesday June 17, 2020**

<b>To,</b> <b>Corporate Services Department</b> <b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001.</b> <b>BSE CODE –540702</b>	<b>To,</b> <b>Corporate Services Department</b> <b>National Stock Exchange of India Limited</b> <b>“Exchange Plaza”, Plot No. C/1,</b> <b>G Block Bandra-Kurla Complex,</b> <b>Bandra (E), Mumbai – 400 051.</b> <b>NSE CODE: LASA</b>
--	--

Dear Sir/Madam,

**Sub: Media Release**

Attached is the copy of Media Release titled “**COVID 19: ICT, Lasa realise success in Favipiravir drug synthesis, to commence production**” issued by the company.

Kindly take the same on your records.

Thanking you

Yours Sincerely

**FOR LASA SUPERGENERICS LIMITED**



**NIDHI KULSHRESHTHA**

**COMPANY SECRETARY AND COMPLIANCE OFFICER**



## Media Release

### **COVID 19: ICT, Lasa realise success in Favipiravir drug synthesis, to commence production**

**Mumbai, June 17, 2020:** API Major, Lasa Supergenerics and Institute of Chemical Technology had come together in the month of March 2020 in effort to bring the antiviral to the market as a promising therapy to fight the ongoing Covid-19 pandemic.

**Commenting on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited,** said Efforts over the last few months has brought success and we are looking to manufacture close to 10,000 doses to begin with and in the meanwhile also apply for the drug licence with competent authorities and continue to seek strategic private investments or Government aid. Our move into human steroid API is in line with the organisations inherent strengths and objectives to diversify.

**Commenting on the antivirals successful synthesis, Prof. Vikas N Telvekar, ICT, Mumbai,** said we are happy to share with you that the Favipiravir molecule has been successfully synthesized in the ICT laboratory on a lab scale and further pilot plan scale up is required.”

Recently in its Q4 results, the company reported a healthy increase in its PAT to Rs 3.63 cr for FY20, as compared to a loss of Rs 12.04 cr in the corresponding period last fiscal.

**About ICT,** Institute of Chemical Technology (ICT) Formerly the University Department of Chemical Technology (UDCT) is a Public deemed University specialized in Chemical Technology located in Mumbai, India. It is focused in training and research in various branches of chemical engineering, chemical technology and pharmacy.

**About Favipiravir,** Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease (COVID-2019). It possesses activity against many RNA viruses. It is a guanine analogue approved for influenza treatment. It can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus, and a recent study reported its activity against 2019-nCoV.

#### **About Lasa Supergenerics Ltd (BSE: 540702; NSE: LASA)**

Incorporated in 2011, Lasa is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea etc.

#### **For more information contact:**

---

Mr. Hitesh Wadhvani  
**Lasa Supergenerics Ltd.**  
Tel: 7798888147  
E-mail: [hitesh@lasalabs.com](mailto:hitesh@lasalabs.com)

Mr Shahab Shaikh / Amruta Desai  
**Concept PR**  
+91 9320897525/ +91 9867891235  
[shahab@conceptpr.com](mailto:shahab@conceptpr.com)/[amruta@conceptpr.com](mailto:amruta@conceptpr.com)



---

**DISCLAIMER:**

*Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*